In patients with T2D, the risks for gastroesophageal reflux disease and related complications are greater with GLP-1 RA ...

Regeneron’s monoclonal antibody trevogrumab, with or without the anti-activin A antibody garetosmab, appears to preserve lean ...

USA: A new study published in Arthritis & Rheumatology found that patients with lupus and type 2 diabetes, including those ...

Patients with systemic lupus erythematosus (SLE) and type 2 diabetes, with and without lupus nephritis (LN), had a lower risk ...

Addressing obesity and fibromyalgia are essential components to managing the most complex patients with psoriatic arthritis, ...

Taiwan: A recent study has found that the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in patients with type ...

This 3-part series looks at the current evidence for the treatment of SUDs. Part 2 reviews the use of GLP-1 receptor agonists and alcohol use disorder.

A major new study reveals that older adults with cancer and type 2 diabetes who take GLP-1 receptor agonist medications (GLP-1RAs) experience significantly better overall survival rates compared to ...

GLP-1 receptor agonists may significantly reduce the risk for cardiovascular events in patients with rheumatoid arthritis treated with Janus kinase inhibitors, according to data presented at the EULAR ...

Obesity has reached pandemic proportions, affecting over 40% of Americans, with a projected increase to 51% of the global population within 12 years if current trends continue. This condition is ...

Protective associations were seen between GLP-1 RA use and colon and rectal cancers. (HealthDay News) — For adults with diabetes and obesity, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are ...

Skye Bioscience's nimacimab fell short of investor and company expectations, but showed encouraging weight-loss results when ...